Permissions

Varian Pharmed Pharmaceutical Company, as a knowledge-based and leading company in the Iranian pharmaceutical industry, has obtained the necessary licenses for the production and sale of its drugs from the relevant authorities. These licenses include approvals from the Ministry of Health and Medical Education of Iran, which are issued based on stringent health and safety standards. The Ministry of Health’s approvals for Iranian pharmaceutical companies not only involve precise examinations of drug formulations and production processes but also include ongoing quality control of the products.

In addition to domestic licenses, Varian Pharmad has strived to comply with international standards such as the European Union’s Good Manufacturing Practices (GMP) and the U.S. Food and Drug Administration (FDA) to expand its markets internationally. These standards guarantee a high level of quality and safety for Varian Pharmad’s products and allow the company to offer its drugs in global markets. Adhering to these standards also helps the company to maintain a competitive edge against international competitors.

In line with maintaining credibility and complying with international laws, Varian Pharmad also actively participates in the ISO certification processes for quality and safety management of its products. These ISO standards help the company ensure that all processes and products operate uniformly at the highest levels of international standards. This commitment to quality and safety not only helps maintain the health of consumers but also enables the company to compete in global markets.

Moreover, Varian Pharmed has been a pioneer in the field of innovative drug delivery technologies such as In Situ Forming Systems and has successfully obtained several international patents. These achievements demonstrate the company’s high capability in innovation and research and development and are considered part of Varian Pharmad’s international credibility. These patents help the company protect its technical knowledge while simultaneously increasing revenue through licensing its technologies.